Sep 6, 2024 | News, Press Releases
We are pleased to announce that Hemera has been selected as one of the 11 finalists for the Italian Master Startup Award (IMSA), the prestigious prize dedicated to scale-ups born from academic research. The award is promoted by the national network of university...
Oct 31, 2023 | Press Releases
The patients will be monitored for 12 months at three Centers of Excellence in Northern Italy. At the starting blocks is the prospective observational clinical study on patients with traumatic and complete spinal cord injury in the acute phase. They will be observed...
Oct 31, 2023 | Press Releases
The prospective observational clinical study is now underway, involving patients with acute, complete traumatic spinal cord injury, who will be monitored over a 12-month period during their neurorehabilitation journey. Authorized by the respective Ethics Committees,...
Jun 8, 2023 | News, Press Releases
REMaST® Recognized as an Orphan Drug for Acute Spinal Cord Injuries The advanced cell therapy REMaST®, developed by Hemera, has been granted orphan drug designation by the European Commission for the treatment of acute spinal cord injuries. This important recognition...
Apr 21, 2023 | News, Press Releases
The Italian Patent and Trademark Office Officially Recognizes the Patent for REMaST® Therapy The positive evaluation by the Italian Patent and Trademark Office has led to the long-awaited recognition of REMaST® therapy, two years after the patent application was...
Feb 8, 2023 | Press Releases, Press Review, Press Review
Interview with Cristiana Vignoli, protagonist of the month on Il CUBo Cristiana Vignoli, CEO of Hemera is the protagonist of the month for February in the online magazine Cubo. In the beautiful interview by Luca de Poli published at the beginning of the month...
